Skip Navigation

Annals of Oncology 2006 17(Supplement 7):vii22-vii26; doi:10.1093/annonc/mdl944
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Clavarezza, M.
Right arrow Articles by Venturini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clavarezza, M.
Right arrow Articles by Venturini, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Taxane-containing chemotherapy in the treatment of early breast cancer patients

M. Clavarezza1, L. Del Mastro1 and M. Venturini2,3,*

1 Oncologia Medica A; 2 Ricerca Traslazionale A, National Cancer Research Institute, Genova, Italy; 3 Oncologia Medica Ospedali Negrar, Verona, Italy

* Correspondence to: Dr M. Venturini, National Cancer Research Institute, L.go Rosanna Benzi, n.10, 16132 Genoa, Italy. Tel: +39-0105600898; Fax: +39-0105600850; E-mail: arco_venturini{at}vodafone.it

In primary breast cancer, taxane-based compared with anthracycline-based adjuvant chemotherapy significantly reduces the relative risk of recurrence (ranging from 17% to 36%) and sometimes improves overall survival. Different dosages and schedules of anthracyclines and taxanes have been tested. Randomized studies comparing sequential versus concurrent administrations are in progress and no data about efficacy are available. However, based on a single randomized trial and on indirect comparisons, safety and tolerability seem to be better with sequential schema. A formal comparison between weekly and every 3 weeks administration of taxanes reported no substantial difference in terms of efficacy. However, taking into account a subgroup analysis of this study, and results coming from metastatic disease, the best way to give taxanes seems to be either weekly paclitaxel or docetaxel every 3 weeks. In the majority of the study, taxane efficacy seems to be independent of hormonal receptor status, i.e. active in both hormonal receptor positive and negative disease. In conclusion, taxane-based adjuvant chemotherapy is a standard option for most early breast cancer patients with node-positive disease. No sufficient and dedicated data are available in node-negative disease.

Key words: early breast cancer, adjuvant chemotherapy, taxanes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. N. Shajahan, A. Wang, M. Decker, R. D. Minshall, M. C. Liu, and R. Clarke
Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity
J. Biol. Chem., February 23, 2007; 282(8): 5934 - 5943.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.